An Israeli medicinal cannabis start-up is one of the latest firms to list on the Australian stock exchange, as the ASX seeks to diversify its traditionally resource-dominant stock offering.

Despite its Israeli roots, eSense-Lab chose the Australian Securities Exchange (ASX) to make its foray into global markets to take advantage of investor appetite here for new technology stocks.

A brainchild of Israeli doctor Yaron Penn, who has spent the past six years refining the technology, the firm produces a product which smells and tastes like cannabis and has many of its medicinal benefits but does not contain a trace of an actual cannabis plant.

Global cannabis software and point of sales solutions company Guardian Data Software (GDS) has announced a partnership with Australian medical cannabis accelerator BuddingTech that will see the organisation act as an analytical engine and business consultancy for GDS clients, while working towards new research initiatives.

BuddingTech, a Sydney-based organisation which emerged in 2015, identifies startups working with cannabis technology and research, and looks to support them towards commercialising their ideas for the Asia Pacific medical cannabis market.

Besides the accelerator, BuddingTech also offers consultation services, and holds a medical cannabis resource database filled with surveys and analytical white paper reports.

The company will expand its clinical research to include autism.

Zelda Therapeutics (ASX:ZLD) has expanded its medical cannabis clinical trial program in Chile to include autism, which is expected to commence in the second half of 2017.

Autism is a lifelong development disability characterized by impairments in social communication and interactions.

The global market for autism diagnosis and treatments is expected to grow to US$412.7 million by 2019.

Global cannabis software and point of sales solutions company Guardian Data Software (GDS) has announced a partnership with Australian medical cannabis accelerator BuddingTech that will see the organisation act as an analytical engine and business consultancy for GDS clients, while working towards new research initiatives.

BuddingTech, a Sydney-based organisation which emerged in 2015, identifies startups working with cannabis technology and research, and looks to support them towards commercialising their ideas for the Asia Pacific medical cannabis market.

Besides the accelerator, BuddingTech also offers consultation services, and holds a medical cannabis resource database filled with surveys and analytical white paper reports.

Ever since Australia moved to legalize medical cannabis, dozens of Australian companies have bloomed and boomed, with shares climbing in value as Australian state governments continue to relax regulations.

But what about the risks still lurking in the nascent market? To succeed, these companies rely heavily on continued government reform. To avoid getting burned, investors should do their homework. Here are a few questions to get started.

Ever since Australia moved to legalize medical cannabis, dozens of Australian companies have bloomed and boomed, with shares climbing in value as Australian state governments continue to relax regulations.

But what about the risks still lurking in the nascent market? To succeed, these companies rely heavily on continued government reform. To avoid getting burned, investors should do their homework. Here are a few questions to get started.

Joint venture company DayaCann is currently harvesting in Chile.

AusCann Group Holdings (ASX:AC8) is in the process of harvesting its first medical cannabis crop located in Chile.

The crop was planted by the DayaCann joint venture, of which AusCann holds 50:50 with Fundacion Daya.

The large open greenhouse grown plants include various strains that have been selected for specific medical usage.

Perth-based MGC Pharmaceuticals has reportedly produced its first cannabinoid extracts at the company’s new European extraction facility. The company told on Monday that it has successfully produced the primary psychoactive compound in cannabis, cannabinoid, at its Slovenia extraction facility.

Tamworth's medical cannabis advocate Lucy Haslam hopes the NSW Premier does her homework before the pair meet in Sydney today.

The meeting was teed up by former premier Mike Baird who was a strong supporter of Mrs Haslam campaign for medical marijuana.

CAMPAIGNER: Medical cannabis advocate Lucy Haslam. Photo: Peter Hardin 200217PHD004